StockNews.AI
LFMD
StockNews.AI
10 hrs

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against LifeMD, Inc. (LFMD)

1. A class action lawsuit targets LifeMD for misleading statements. 2. Plaintiffs claim LifeMD overstated its competitive position. 3. Concerns arise over rising customer acquisition costs. 4. Lawsuit covers purchases made between May 7 and August 5, 2025. 5. Investors urged to contact law firm by October 27, 2025.

3m saved
Insight
Article

FAQ

Why Very Bearish?

Legal issues typically lead to negative sentiment and stock price declines, as seen with other firms facing similar lawsuits. This lawsuit could significantly undermine investor confidence and valuation metrics.

How important is it?

The nature of the allegations indicates serious corporate governance issues that could deter investors.

Why Short Term?

Immediate legal proceedings can create volatility in the stock, impacting short-term trading behavior. Historical instances reflect swift market reactions to lawsuits.

Related Companies

WegovyZepbound
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, Defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Investors who purchased or otherwise acquired shares of LifeMD should contact the Firm prior to the October 27, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com. Please visit our website at http://www.gme-law.com for more information about the firm.

Related News